Oric Pharmaceuticals (ORIC) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Key program updates and clinical development

• Focused on two late-stage clinical programs: rinzimetostat (PRC2 inhibitor for prostate cancer) and enosartib (brain-penetrant lung cancer compound targeting EGFR mutations).

• Rinzimetostat recently entered its first phase III study (HIMALAYA-1) in CRPC; enosartib phase III expected to start next year.

• HIMALAYA-1 is a global study with hundreds of sites in over 24 countries.

• Plans underway for additional phase III studies (HIMALAYA-2 and HIMALAYA-3) in different prostate cancer settings, with at least one starting next year.

• Program update for rinzimetostat expected later this year, potentially including trial progress or new data.

Competitive landscape and trial implications

• Pfizer’s MEVPRO-1 phase III readout in Q4 is seen as a positive signal for the PRC2 inhibitor class; a big miss is considered statistically unlikely.

• HIMALAYA-1 and MEVPRO-1 have similar designs, but HIMALAYA-1 caps control arm composition to avoid skew.

• MEVPRO-2, with a control arm of enzalutamide only, is expected to read out within 12 months and is considered highly likely to be positive.

• Positive results from MEVPRO-1 and MEVPRO-2 would further de-risk the mechanism for the entire class and future studies.

• Rinzimetostat-darolutamide combination is differentiated by longer half-life, lower dose, and lack of CYP induction compared to Pfizer’s regimen.

Efficacy, safety, and clinical benchmarks

• Clinically meaningful PFS improvement is defined as a hazard ratio of 0.66 or better, with a median PFS of 10+ months in the treatment arm.

• All-oral regimens with double-digit PFS are considered highly meaningful for patients and clinicians.

• Rinzimetostat’s safety profile is expected to be favorable due to lower dosing and combination with darolutamide.

• Abiraterone remains a significant part of the treatment paradigm, with steady usage over the past five years.